DEYMED Diagnostic

DEYMED Diagnostic operates as a specialized European medical-device manufacturer focused on neurodiagnostics and neurostimulation. Its offering covers TruScan EEG, TruTrace EMG, SomniPro PSG, NeuroTablet RS, DuoMAG MP-Quad, and the TruScan EEG BrainFeedback Module, creating a broader modality footprint than a single-product diagnostic vendor. The company combines hardware, clinical software, neurofeedback capabilities, and accessories such as EEG caps, electrodes, needles, and sensors. This integrated approach can support hospitals, sleep laboratories, neurophysiology departments, psychiatric practices, and research users through a common supplier relationship. Publicly available comparable-company information is limited, so no verified competitor set can be established for this profile. The company is nevertheless referenced alongside established neurological-device providers in a 2025 Guillain-Barre diagnostics market report, including Cadwell, Natus Medical, Nihon Kohden, Medtronic, Bionen Medical Devices, Neurosoft, and Alpine Biomed. Those names indicate the competitive context, but not equivalent product coverage or market share. DEYMED’s clearest differentiator is its combination of EEG, EMG, PSG, TMS, and neurofeedback products within one portfolio.

DEYMED Diagnostic appears to follow a steady, product-led growth trajectory rather than a venture-financed expansion model. Founded in 1997 and still active, the company has developed a multi-modality portfolio spanning EEG, EMG, PSG, TMS, and neurofeedback. The product range suggests incremental expansion from core neurophysiology equipment into adjacent sleep, stimulation, psychiatry, and ambulatory-care use cases. Intellectual-property activity provides two identifiable technical inflection points: publications on Jul 4, 2022 and Jul 8, 2022 related to a monophasic TMS stimulator, followed by Mar 8, 2023 publications concerning stimulation-artifact reduction. These filings indicate continued engineering work in stimulation technology, although they do not confirm commercialization timing. Recruitment activity reported in November 2025, particularly for neurophysiological technology roles and internships, points to continued capability building. The company’s inclusion in several market reports during March-May 2025 provides evidence of category visibility, while website activity indicates international reach across clinical and research applications.